Thereby, it is feasible that the PVT1–MYC fusion can have a potential oncogenic effect and could represent a possible biomarker due to its expression in several types of cancer such as colon, breast, and esophagus, leukemia, and medulloblastoma.61, 62, 63, 64, 65 However, there were other PVT1 fusions in which their gene partner shares genes across other types of cancer such as IGL, an immunoglobin already identified to form fusions with PCG such as MYC in multiple myeloma.66 This evidence concerns the gene MYC and leukemia.